Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy
Source abstract
Abstract
Immune checkpoint blockade (ICB) therapy, particularly PD1/PDL1 inhibition, has demonstrated success in bolstering durable responses in patients. However, the response rate remains below 30 %. In this study, we developed a polymeric bispecific antibody (BsAb) targeting PD1/PDL1 to enhance ICB therapy. Specifically, poly(L-glutamic acid) (PGLU) was conjugated with a double cyclic Fc binding peptide, Fc-III-4C, through condensation reactions between the -COOH group of PGLU and the -NH2 group of Fc-III-4C. This conjugate was then mixed with αPD1 and αPDL1 monoclonal antibodies (mAbs) in an aqueous solution. Mechanistically, the PD1/PDL1 BsAb (BsAbαPD1+αPDL1) acts as a bridge between tumor cells and CD8+ T cells, continuously activating CD8+ T cells to a greater extent. This leads to significantly suppressed tumor growth and prolonged survival in a mouse model of colon cancer compared to treatment with either a single mAb or a mixture of free mAbs. The tumor suppression rate achieved by the BsAbαPD1+αPDL1 was 90.1 %, with a corresponding survival rate of 83.3 % after 48 days. Thus, this study underscores the effectiveness of the BsAbαPD1+αPDL1 as a synchronizing T cell engager and dual ICBs, offering theoretical guidance for clinical ICB therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · CAR-T cell therapy research · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Big opportunities for small molecules in immuno-oncology10.1038/nrd4596 ↗
2. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications10.1038/s41423-020-0488-6 ↗
3. A decade of immune-checkpoint inhibitors in cancer therapy10.1038/s41467-020-17670-y ↗
4. Beyond immune checkpoint blockade: emerging immunological strategies10.1038/s41573-021-00155-y ↗
5. Revisiting the PD-1 pathway
6. Organic-solvent-free “lego-like” modular preparation of fab-nondestructive antibody-drug conjugates with ultra-high drug-to-antibody ratio
7. Pd-l1 expression in colon cancer and its relationship with clinical prognosis
8. PD-L1 promotes tumor growth and progression by activating wip and β-catenin signaling pathways and predicts poor prognosis in lung cancer10.1038/s41419-020-2701-z ↗
9. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway10.1038/s41401-020-0366-x ↗
10. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth10.1016/j.cell.2015.08.052 ↗
11. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer10.1056/NEJMoa1801005 ↗
12. Phase i study of single-agent anti-programmed death-1 (mdx-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates10.1200/JCO.2009.26.7609 ↗
13. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer10.1056/NEJMoa1200690 ↗
14. Azide-masked resiquimod activated by hypoxia for selective tumor therapy10.1002/adma.202207733 ↗
15. Pembrolizumab versus docetaxel for previously treated, pd-l1-positive, advanced non-small-cell lung cancer (keynote-010): a randomised controlled trial10.1016/S0140-6736(15)01281-7 ↗
16. Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer10.1056/NEJMoa1606774 ↗
17. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer10.1056/NEJMoa1504627 ↗
18. T cell-engaging therapies — bites and beyond10.1038/s41571-020-0347-5 ↗
19. Nanobody-based bispecific t-cell engager (nb-bite): a new platform for enhanced t-cell immunotherapy
20. Blinatumomab: a cd19/cd3 bispecific t cell engager (bite) with unique anti-tumor efficacy10.3109/10428194.2016.1161185 ↗
21. Tebentafusp, a tcr/anti-cd3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma10.1158/1078-0432.CCR-20-1247 ↗
22. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study10.1016/S1470-2045(22)00335-7 ↗
23. Teclistamab, a b-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (majestec-1): a multicentre, open-label, single-arm, phase 1 study10.1016/S0140-6736(21)01338-6 ↗
24. Emicizumab, a bispecific antibody to factors ix/ixa and x/xa, does not interfere with antithrombin or tfpi activity in vitro10.1055/s-0038-1636538 ↗
25. A high throughput bispecific antibody discovery pipeline
26. Bispecific antibodies: a mechanistic review of the pipeline10.1038/s41573-019-0028-1 ↗
27. Development of the double cyclic peptide ligand for antibody purification and protein detection10.1021/acs.bioconjchem.6b00170 ↗
28. An fc binding peptide-based facile and versatile build platform for multispecific antibodies10.1021/acs.nanolett.3c00071 ↗
29. Characterization of the Fc-III-4C-based recombinant protein expression system by using carbonic anhydrase as the model protein10.1016/j.pep.2020.105761 ↗
30. Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses10.1039/D0SC00017E ↗
31. Cisplatin loaded poly(l-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for potential cancer therapy: preparation, in vitro and in vivo evaluation10.1166/jbn.2016.2152 ↗
32. Glucose-sensitive polymer nanoparticles for self-regulated drug delivery10.1039/C6CC02202B ↗
33. Poly(l-glutamic acid)--anticancer drug conjugates10.1016/S0169-409X(02)00045-5 ↗
34. Immune checkpoint inhibitors: recent progress and potential biomarkers10.1038/s12276-018-0191-1 ↗
35. Erratum: molecular mechanisms of t cell co-stimulation and co-inhibition
36. Cancer immunotherapy comes of age10.1038/nature10673 ↗
37. PD-1/PD-L1 based combinational cancer therapy: icing on the cake10.3389/fphar.2020.00722 ↗
38. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
39. Cisplatin nanoparticles promote intratumoral CD8(+) T cell priming via antigen presentation and t cell receptor crosstalk10.1021/acs.nanolett.2c00478 ↗
40. Bispecific antibody PL-L1 x CD3 boosts the anti-tumor potency of the expanded vgamma2vdelta2 t cells
41. Moving t memory stem cells to the clinic10.1182/blood-2012-11-468660 ↗
42. Polarization diversity of human CD4+ stem cell memory t cells10.1016/j.clim.2015.04.010 ↗
43. Il-12 enhances the natural killer cell cytokine response to ab-coated tumor cells10.1172/JCI0215950 ↗
44. Stepwise regulation of th1 responses in autoimmunity: il-12-related cytokines and their receptors10.1097/01.MIB.0000172808.03877.4d ↗
45. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current tnf-α inhibitors in therapeutics10.3390/ijms22052719 ↗
46. Photodynamic-chemodynamic cascade reactions for efficient drug delivery and enhanced combination therapy10.1002/advs.202002927 ↗